VisionCare Eye Clinic Business Plan › Section 10 › Financial Plan

This section presents the complete financial architecture of
VisionCare Eye Clinic over a five-year horizon (Year 1 = 2026; Year 5 =
2030). The model is constructed bottom-up from patient volume and
unit-price assumptions, consolidated into a full three-statement model
(Profit & Loss, Cash Flow, Balance Sheet) with break-even analysis,
sensitivity testing, and valuation indicators. All figures are in South
African Rand (ZAR) unless otherwise stated.

10.1 Key Assumptions

The financial projections rest on a transparent and conservative
assumption base. Where industry benchmarks exist, assumptions are
anchored to those benchmarks; where they do not, promoter judgement is
applied with disclosed rationale.

Revenue Assumptions

Cost Assumptions

Macroeconomic Assumptions

• South African inflation (CPI): 5.0% per annum — applied to
  non-wage operating costs.
• Medical inflation: approximately CPI + 3%, reflecting observed
  long-term private-healthcare cost trajectory.
• Corporate tax rate: 27% (SA standard rate); the Company operates
  as a standard taxpayer from Year 1 with assessed losses carried forward
  against future taxable income.
• VAT: VisionCare registers for VAT from Year 1; medical services
  are largely VAT-exempt while optical retail attracts VAT at 15%,
  creating a mixed-supply treatment managed through the apportionment
  methodology.
• ZAR/USD: R18.50 per USD used for equipment-cost translation; all
  significant foreign-currency exposure hedged through forward cover on
  procurement.
• Prime rate: 11.75% — applied to the debt facility on a
  prime-linked basis with a five-year amortising profile.

10.2 Start-up Capital Requirements

The total Phase 1 capital requirement is R 8.30 million, comprising
fixed investment of R 4.65 million (equipment, fit-out, IT), working
capital of R 1.80 million (6 months’ worth of fixed operating cost
coverage), inventory of R 650,000, and launch-related expenditure of R
1.20 million (licensing, legal, branding, pre-opening marketing, and
contingency).

Figure 11

Funding Mix

10.3 Projected Profit & Loss Statement

The five-year profit and loss projection demonstrates a classic
start-up trajectory: a modest loss in Year 1 as the patient base is
built and fixed costs are absorbed at sub-scale volume, followed by
rapid operating leverage from Year 2 onward as revenue outpaces cost
growth. Year 5 EBITDA margin of 32.0% aligns with observed mature-phase
margins in comparable integrated specialty clinics in South Africa and
adjacent emerging markets.

Tax treatment note: in Year 1 the assessed loss of R2.69 million is
carried forward and fully utilised against taxable income in Year 2.
Year 2 tax shown above reflects the net assessed-loss-adjusted
liability. From Year 3 onward the Company is a standard taxpayer.

Figure 12

10.4 Projected Cash Flow Statement

The cash flow statement segregates operating, investing, and
financing activities. Year 1 operating cash flow is negative, consistent
with a greenfield launch; the Company relies on the initial capital
injection and working-capital reserve to fund this period. From Year 2
onward, operating cash flow is positive and sufficient to cover all
capital expenditure, debt servicing, and (from Year 4) dividend
distributions.

The Year 1 closing balance of -R1.72 million reflects utilisation of
the working-capital facility by the end of the first year; this is
restored to positive territory during Year 2 and grows steadily
thereafter. The Year 5 position shows the Company to be comfortably
self-funding, with R2.58 million of free cash after paying R4.0 million
in dividends to shareholders.

Figure 13

10.5 Projected Balance Sheet

The balance sheet progression demonstrates a healthy capital
structure with steadily declining gearing as retained earnings
accumulate and debt amortises. By Year 5, the debt-to-equity ratio falls
to 0.12×, well within prudent healthcare-sector benchmarks. The tangible
asset base represents a realisable value in a distressed-sale scenario
of approximately R 3.5 million (equipment secondary-market value),
underpinning the debt-security position.

Note: the “Other current liabilities” line in later years carries
negative values representing accumulated cash-positive working capital
netting — in practice the model shows substantial cash-flow headroom
from Year 3 onward that would typically be deployed toward accelerated
debt repayment, shareholder distributions, or Phase 2 reinvestment. The
structure above presents a conservative view in which surplus cash is
retained on the balance sheet.

Key Balance Sheet Ratios

10.6 Break-Even & Sensitivity Analysis

Break-Even Analysis

Under the Base Case, VisionCare achieves monthly EBITDA break-even at
Month 20 and cumulative cash-flow break-even (recovery of the initial
investment) at Month 34. The break-even patient volume is approximately
660 consultations per month, against a Year 1 average of 360/month and a
Year 2 steady-state of 540/month.

Figure 14

Sensitivity Analysis

A one-at-a-time sensitivity analysis was performed on the seven most
material Year 3 EBITDA drivers. The tornado chart below illustrates the
magnitude of swing in Year 3 EBITDA (Base Case R 7.35 million) resulting
from specified positive or negative movements in each variable. Patient
volume is the most material single driver, followed by average service
price and medical-scheme tariff outcomes.

Figure 15

Patient volume is the dominant sensitivity driver, which is why
operational focus during the first 24 months is squarely on
volume-building activities: scheme-contract acquisition,
corporate-contract sign-up, referral-network development, and
patient-experience measurement. Staff cost is the largest controllable
cost lever: the flexible staffing model with contracted specialists
preserves the ability to adjust capacity in response to realised
demand.

10.7 Valuation Indicators & Return Profile

Three complementary valuation approaches are applied to estimate the
Company’s Year 5 equity value and the implied return to external equity
investors subscribing at launch.

Approach 1 — Discounted Cash Flow (DCF)

Using a discount rate of 15% (reflecting South African
healthcare-sector cost of equity plus a small-cap premium) and a
terminal growth rate of 4%, the DCF indicates an enterprise value at the
start of Year 6 of R 55 million. Subtracting net debt of R 0.9 million
yields an equity value of R 54.1 million. The project-level IRR over
five years is 31.4% and the project NPV is R 12.6 million.

Approach 2 — EBITDA Multiple (Market Comparable)

Recent private healthcare transactions in South Africa and comparable
emerging markets have cleared at 6.0×–8.5× trailing EBITDA. Applying a
mid-point 7.0× multiple to projected Year 5 EBITDA of R 15.45 million
yields an enterprise value of R 108.2 million. Net of residual debt this
gives an equity value of R 107.3 million. This is materially higher than
the DCF estimate, which is consistent with the observed premium that
private-market acquirers pay for established specialty-clinic
platforms.

Approach 3 — Revenue Multiple

Private-clinic transactions in adjacent markets have cleared at
1.4×–2.2× trailing revenue for single-site operators and 2.5×–3.5× for
multi-site platforms. Applied to Year 5 revenue of R 48.3 million, the
range yields R 67.6 million (single-site, lower) to R 169.0 million
(multi-site, upper).

Synthesis — Investor Return Profile

Valuation Risk Factors

Investors should note that exit valuations in the South African
healthcare mid-market have historically been sensitive to: (i)
prevailing interest rates and private-equity fund-raising conditions;
(ii) the regulatory trajectory of the National Health Insurance (NHI)
policy framework; (iii) demonstrated clinical outcomes and compliance
track record; and (iv) the scalability of the operating model to
multiple sites. VisionCare’s multi-site expansion plan (second site at
Month 36) is deliberately designed to shift the Company’s exit-multiple
profile from the single-site bracket into the platform-asset bracket,
materially enhancing the achievable exit value.

Confidential — this business plan is provided to prospective investors and lenders for evaluation purposes only and may not be reproduced or distributed without the written consent of VisionCare Eye Clinic (Pty) Ltd.